Josh Cohen is the Co-CEO and Co-Founder at Amylyx Pharmaceuticals Inc. where he has invented and developed AMX0035 and brought it through clinical trials with the help of Justin Klee his co-founder and the other Co-CEO at Amylyx as well as with help from their team and the ALS and Alzheimer's Communities who have guided us and advised us at every step of the way.